A Randomized, Open-Label, Non-inferiority Clinical Trial Assessing 7 Versus 14 Days of Antimicrobial Therapy for Severe Multidrug-Resistant Gram-Negative Bacterial Infections: The OPTIMISE Trial Protocol.
Beatriz ArnsJaqueline Driemeyer Correia HorvathGabriela Soares RechGuilhermo Prates SesinCrepin Aziz Jose Oluwafoumi AganiBruna Silveira da RosaTiago Marcon Dos SantosLiliane Spencer Bittencourt BrochierAlexandre Biasi CavalcantiBruno Martins TomaziniAdriano Pereira PagliaViviane Cordeiro VeigaGiovana Marssola NascimentoAndre C KalilAlexandre Prehn ZavasckiPublished in: Infectious diseases and therapy (2023)
ClinicalTrials.gov, NCT05210387. Registered on 27 January 2022. Seven Versus 14 Days of Antibiotic Therapy for Multidrug-resistant Gram-negative Bacilli Infections (OPTIMISE).
Keyphrases
- gram negative
- multidrug resistant
- clinical trial
- open label
- drug resistant
- phase ii
- acinetobacter baumannii
- phase iii
- study protocol
- klebsiella pneumoniae
- randomized controlled trial
- staphylococcus aureus
- early onset
- phase ii study
- squamous cell carcinoma
- radiation therapy
- double blind
- cystic fibrosis
- pseudomonas aeruginosa